Unique ID issued by UMIN | UMIN000008349 |
---|---|
Receipt number | R000009819 |
Scientific Title | A phase I clinical trial of prophylactic extended-field radiotherapy of pelvic and para-aortic lymph nodes using carbon-ion beams and concurrent cisplatin chemotherapy for locally advanced squamous cell carcinoma of the uterine cervix |
Date of disclosure of the study information | 2012/08/01 |
Last modified on | 2015/07/07 20:51:01 |
A phase I clinical trial of prophylactic extended-field radiotherapy of pelvic and para-aortic lymph nodes using carbon-ion beams and concurrent cisplatin chemotherapy for locally advanced squamous cell carcinoma of the uterine cervix
Cervix-V (Protocol 1207)
A phase I clinical trial of prophylactic extended-field radiotherapy of pelvic and para-aortic lymph nodes using carbon-ion beams and concurrent cisplatin chemotherapy for locally advanced squamous cell carcinoma of the uterine cervix
Cervix-V (Protocol 1207)
Japan |
Uterine cervical cancer
Obstetrics and Gynecology | Radiology |
Malignancy
NO
To evaluate the saftey and the toxicity of prophylactic extended-field radiotherapy of pelvic and para-aortic lymph nodes using carbon ion radiotherapy and concurrent cisplatin chemotherapy for locally advanced squamous cell carcinoma of the uterine cervix
Safety
Confirmatory
Explanatory
Phase I
Acute toxicity of organ at risks
Primary response rate by recommended dose in 6 months after treatment
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine | Maneuver |
5 weeks
Carbon ion radiotherapy: 72.0 GyE / 20 fractions
Chemotherapy: weekly cisplatin 30-40 mg / m2 for 5 weeks.
20 | years-old | <= |
70 | years-old | >= |
Female
1. Squamous cell carcinoma of the uterine cervix
2. International Federation of Gynecology and Obstetrics (FIGO) Stage IIB(>= 4 cm in diameter), III, or IVA disease
3. No para-aortic lymph nodes >= 1 cm in minimum diameter on CT images
4. The tumor had to be grossly measurable.
5. Age between 20 and 70 years
6. Performance status 0 - 2
7. Patients with no histories of prior chemotherapy or pelvic radiotherapy for cervical cancer
8. Normal organ function
(WBC >= 3000/mm3,Hb >= 10g/dl, Plt>= 100,000/mm3, T-Bil.<= 1.5mg/dl, AST(GOT) and ALT(GPT) <= 100IU/dl, Cre <= 1.5mg/dl, CCR >= 50ml/min, ECG normal or require no treatment
9. Estimated life expectancy of _6 months
10. Written informed consent
1. Severe complicating illness
2. Active double cancer
3. Rectal invasion
4. History of pelvic radiotherapy
5. History of prior chemotherapy
6. medical, psychological or others reason that primary doctor think ineligible
12
1st name | |
Middle name | |
Last name | Masaru Wakatsuki |
National Institute of Radiological Sciences
Research Center Hospital for Charged Particle Therapy
4-9-1 Anagawa, Inage-ku, Chiba-city, Chiba, 263-8555 JAPAN
043-206-3306
waka@nirs.go.jp
1st name | |
Middle name | |
Last name | Masaru Wakatsuki |
National Institute of Radiological Sciences
Research Center Hospital for Charged Particle Therapy
4-9-1 Anagawa, Inage-ku, Chiba-city, Chiba, 263-8555 JAPAN
043-206-3306
http://www.nirs.go.jp/hospital/index.shtml
waka@nirs.go.jp
National Institute of Radiological Sciences
National Institute of Radiological Sciences
NO
放射線医学総合研究所(千葉県)
2012 | Year | 08 | Month | 01 | Day |
http://www.nirs.go.jp/hospital/conform/pdf/06_ic_1207.pdf
Unpublished
No longer recruiting
2012 | Year | 06 | Month | 06 | Day |
2012 | Year | 08 | Month | 01 | Day |
2016 | Year | 03 | Month | 31 | Day |
2012 | Year | 07 | Month | 04 | Day |
2015 | Year | 07 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009819